Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Variations in TP53, RB1, and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer.

In vivo (Athens, Greece) - 1 Jan 2000

Holeckova Klaudia Hives, Hives Mark, Grendar Marian, Drobkova Henrieta Blahusiak, Kliment Jan

Abstract excerpt

BACKGROUND/AIM: This report aimed to present identified variants with pathogenic potential in three genes - TP53, PTEN, and RB1 - in a selected sample of patients with metastatic castration-resistant prostate cancer (mCRPC) with or without the presence of circulating tumor cells (CTCs) and splice variant AR-V7. MATERIALS AND METHODS: Next generation sequencing was performed on an Illumina platform to analyse the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Metastasis
Share to Neoplastic Cells, Circulating

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to PTEN Phosphohydrolase

Share to Receptors, Androgen

Share to Retinoblastoma Binding Proteins

Share to Slovakia

Source

Open in PubMed Open full text

Identifiers

PMID: 39477439
DOI: 10.21873/invivo.13737
PMCID: PMC11535959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Variations in TP53, RB1, and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer.PMID 39477439Read ↗

The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐AnalysisSemantic proximity Read ↗

Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.Semantic proximity Read ↗

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.Semantic proximity Read ↗

Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer.Semantic proximity Read ↗

Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.Semantic proximity Read ↗

Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC).Semantic proximity Read ↗

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read ↗

Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.Semantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.